Introduction: Recently, new clinical trial designs involving biomarkers have been studied and proposed in cancer clinical research, in the hope of incorporating the rapid growing basic research into clinical practices.
Sources of data: Journal articles related to various biomarkers and their role in cancer clinical trial, articles and books about statistical issues in trial design, and regulatory website, documents, and guidance for submission of targeted cancer therapies.
Areas of agreement: The drug development process involves four phases. The confirmatory Phase III is essential in regulatory approval of a special treatment.
Areas of controversy: Regulatory agency has restrictions on confirmatory trials 'using adaptive designs'. No rule of thumb to pick the most appropriate design for biomarker-related trials.
Growing points: Statistical issues to solve in new designs. Regulatory acceptance of the 'newly proposed trial designs'.
Areas timely for developing research: Biomarker-related trial designs that can resolve the statistical issues and satisfy the regulatory requirement.
Keywords: adaptive design; biomarker; clinical trial; personalized medicine.
© The Author 2015. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: firstname.lastname@example.org.